Biofil Chemicals & Pharmaceuticals Ltd
Incorporated in 1993, Biofil Chemicals and Pharmaceuticals Ltd manufactures pharmaceutical bulk drugs[1]
- Market Cap ₹ 85.6 Cr.
- Current Price ₹ 52.7
- High / Low ₹ 92.0 / 40.4
- Stock P/E 153
- Book Value ₹ 11.5
- Dividend Yield 0.00 %
- ROCE 4.12 %
- ROE 3.03 %
- Face Value ₹ 10.0
Pros
- Company is almost debt free.
- Company is expected to give good quarter
Cons
- Stock is trading at 4.57 times its book value
- Though the company is reporting repeated profits, it is not paying out dividend
- The company has delivered a poor sales growth of 2.38% over past five years.
- Company has a low return on equity of 3.43% over last 3 years.
- Earnings include an other income of Rs.0.31 Cr.
- Company has high debtors of 419 days.
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Healthcare Healthcare Pharmaceuticals & Biotechnology Pharmaceuticals
Quarterly Results
Figures in Rs. Crores
Profit & Loss
Figures in Rs. Crores
Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
7.17 | 5.86 | 13.17 | 13.45 | 12.36 | 23.13 | 29.69 | 35.75 | 22.38 | 30.04 | 40.04 | 33.40 | |
6.21 | 5.12 | 12.30 | 10.84 | 11.43 | 22.11 | 27.87 | 34.15 | 21.05 | 28.88 | 39.23 | 32.55 | |
Operating Profit | 0.96 | 0.74 | 0.87 | 2.61 | 0.93 | 1.02 | 1.82 | 1.60 | 1.33 | 1.16 | 0.81 | 0.85 |
OPM % | 13.39% | 12.63% | 6.61% | 19.41% | 7.52% | 4.41% | 6.13% | 4.48% | 5.94% | 3.86% | 2.02% | 2.54% |
0.06 | 0.46 | 0.53 | 0.14 | 0.10 | 0.10 | 0.17 | 0.80 | 0.15 | 0.10 | 0.49 | 0.31 | |
Interest | 0.15 | 0.21 | 0.15 | 0.16 | 0.15 | 0.16 | 0.12 | 0.07 | 0.04 | 0.04 | 0.04 | 0.04 |
Depreciation | 0.22 | 0.25 | 0.26 | 0.28 | 0.30 | 0.37 | 0.41 | 0.41 | 0.43 | 0.43 | 0.40 | 0.38 |
Profit before tax | 0.65 | 0.74 | 0.99 | 2.31 | 0.58 | 0.59 | 1.46 | 1.92 | 1.01 | 0.79 | 0.86 | 0.74 |
Tax % | 20.00% | 20.27% | 20.20% | 22.51% | 20.69% | 20.34% | 17.81% | 34.90% | 31.68% | 29.11% | 17.44% | 24.32% |
0.52 | 0.59 | 0.78 | 1.79 | 0.47 | 0.48 | 1.21 | 1.24 | 0.70 | 0.56 | 0.71 | 0.56 | |
EPS in Rs | 0.32 | 0.36 | 0.48 | 1.10 | 0.29 | 0.29 | 0.74 | 0.76 | 0.43 | 0.34 | 0.44 | 0.34 |
Dividend Payout % | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Compounded Sales Growth | |
---|---|
10 Years: | 19% |
5 Years: | 2% |
3 Years: | 14% |
TTM: | -17% |
Compounded Profit Growth | |
---|---|
10 Years: | -1% |
5 Years: | -14% |
3 Years: | -7% |
TTM: | -21% |
Stock Price CAGR | |
---|---|
10 Years: | 30% |
5 Years: | 32% |
3 Years: | -2% |
1 Year: | -17% |
Return on Equity | |
---|---|
10 Years: | 6% |
5 Years: | 4% |
3 Years: | 3% |
Last Year: | 3% |
Balance Sheet
Figures in Rs. Crores
Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Equity Capital | 16.27 | 16.27 | 16.27 | 16.27 | 16.27 | 16.27 | 16.27 | 16.27 | 16.27 | 16.27 | 16.27 | 16.27 |
Reserves | -8.41 | -7.86 | -5.37 | -3.58 | -3.11 | -2.62 | -1.39 | -0.14 | 0.56 | 1.03 | 1.93 | 2.51 |
2.87 | 2.98 | 1.37 | 1.43 | 1.56 | 1.64 | 1.19 | 0.43 | 0.46 | 0.52 | 0.44 | 0.47 | |
3.87 | 2.36 | 11.87 | 7.72 | 9.44 | 8.93 | 26.30 | 16.68 | 1.44 | 13.58 | 28.44 | 31.71 | |
Total Liabilities | 14.60 | 13.75 | 24.14 | 21.84 | 24.16 | 24.22 | 42.37 | 33.24 | 18.73 | 31.40 | 47.08 | 50.96 |
9.17 | 9.06 | 8.98 | 9.16 | 9.25 | 10.29 | 10.09 | 9.78 | 9.42 | 9.00 | 8.62 | 8.34 | |
CWIP | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Investments | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
5.43 | 4.69 | 15.16 | 12.68 | 14.91 | 13.93 | 32.28 | 23.46 | 9.31 | 22.40 | 38.46 | 42.62 | |
Total Assets | 14.60 | 13.75 | 24.14 | 21.84 | 24.16 | 24.22 | 42.37 | 33.24 | 18.73 | 31.40 | 47.08 | 50.96 |
Cash Flows
Figures in Rs. Crores
Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
0.21 | 0.01 | 0.14 | 0.71 | 0.46 | 1.26 | 0.89 | 1.11 | -0.22 | -0.11 | 2.39 | -1.92 | |
-0.24 | -0.17 | -0.19 | -0.48 | -0.38 | -1.41 | -0.21 | -0.10 | -0.07 | -0.01 | -0.02 | -0.10 | |
0.07 | 0.11 | 0.10 | -0.11 | -0.02 | -0.08 | -0.57 | -0.83 | -0.01 | 0.02 | -0.12 | 0.00 | |
Net Cash Flow | 0.04 | -0.05 | 0.05 | 0.13 | 0.06 | -0.24 | 0.12 | 0.18 | -0.30 | -0.11 | 2.25 | -2.03 |
Ratios
Figures in Rs. Crores
Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Debtor Days | 208.72 | 227.35 | 387.45 | 311.00 | 383.31 | 189.84 | 365.25 | 175.81 | 116.94 | 249.08 | 301.10 | 418.77 |
Inventory Days | 20.53 | 15.99 | 3.46 | 7.29 | 38.11 | 21.73 | 24.37 | 48.85 | 24.20 | 16.11 | 24.81 | 39.53 |
Days Payable | 276.79 | 198.49 | 400.98 | 304.52 | 341.46 | 156.66 | 373.80 | 178.39 | 11.25 | 168.39 | 268.08 | 366.78 |
Cash Conversion Cycle | -47.54 | 44.85 | -10.07 | 13.76 | 79.95 | 54.90 | 15.82 | 46.27 | 129.88 | 96.80 | 57.83 | 91.52 |
Working Capital Days | 70.25 | 137.65 | 86.47 | 126.46 | 150.90 | 76.69 | 70.32 | 68.51 | 132.76 | 110.57 | 73.38 | 119.23 |
ROCE % | 7.66% | 8.59% | 9.64% | 18.72% | 5.06% | 5.00% | 10.08% | 12.20% | 6.20% | 4.73% | 4.94% | 4.12% |
Documents
Announcements
-
Announcement under Regulation 30 (LODR)-Newspaper Publication
31 May - Submission of Publication of Financial Results in the Newspaper pursuant to Regulation 47 of SEBI (Listing Obligations and Disclosure Requirement) Regulations, 2015.
- Audited Financial Result For The Financial Year Ended 31.03.2025 30 May
-
Board Meeting Outcome for Outcome Of Board Meeting Held On Friday 30Th May, 2025 Pursuant To Regulation 30 Of SEBI (LODR) Regulations, 2015.
30 May - Audited FY25 results approved; profit before tax Rs 73.62 lakhs; unmodified audit opinion confirmed.
-
Compliances-Reg.24(A)-Annual Secretarial Compliance
27 May - Annual Secretarial Compliance Report filed; delay in appointing Company Secretary noted from Dec 2024 to Apr 2025.
-
Board Meeting Intimation for Intimation For Meeting Of Board Of The Directors (Serial No.02/2025-26) Of The Company Scheduled To Be Held On Friday, 30Th May, 2025.
22 May - Board meeting on May 30 to approve FY25 audited financial results and reopen trading window.
Annual reports
-
Financial Year 2024
from bse
-
Financial Year 2023
from bse
-
Financial Year 2022
from bse
-
Financial Year 2021
from bse
-
Financial Year 2020
from bse
-
Financial Year 2019
from bse
-
Financial Year 2018
from bse
-
Financial Year 2017
from bse
-
Financial Year 2016
from bse
-
Financial Year 2015
from bse
-
Financial Year 2014
from bse
-
Financial Year 2013
from bse
-
Financial Year 2012
from bse
-
Financial Year 2011
from bse
-
Financial Year 2010
from bse
Business Overview:[1][2]
Company deals in manufacturing and trading of pharmaceutical and also manufactures plastic products required for packing pharmaceutical and other plastic products. Further, it also deals in providing job work facility in respect of manufacturing of pharmaceuticals drugs via 2 units viz. Pharmaceutical Division & Chemicals Division.